Stocks · Healthcare · Drug Manufacturers - Specialty & Generic
Pacira BioSciences, Inc. PCRX
$25.05 -0.63% Close, Oct 5, 2026 · NASDAQ · Market cap $991.6M
High qualityInexpensive vs sector
Next earnings report: Nov 5, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Operating margin widened to 2.5% from -14.8% a year earlier.
- The diluted share count fell 11.3% in a year, mainly through buybacks.
- The stock is in an uptrend: above its 200-day average for 34 trading days, with the 50-day average above the 200-day.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 6, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Bottom 42%
- FCF growth (TTM, YoY)Top 28%
- Revenue growth, 3-year CAGRBottom 32%
- Revenue growth accelerationTop 36%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalTop 30%
- Gross marginTop 32%
- Operating marginTop 38%
- Cash conversion (OCF / net income)Top 10%
- Accruals (lower is better)Top 24%
- Net debt / EBITDA (lower is better)Bottom 42%
- Interest coverTop 40%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldTop 25%
- Free-cash-flow yieldTop 3%
- EBITDA / enterprise valueTop 10%
- Sales / enterprise valueTop 20%
- P/E vs own 5-year history (lower is better)Top 50%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthBottom 42%
- 6-month returnTop 47%
- 1-year return vs S&P 500Bottom 44%
- Distance from 52-week highTop 17%
- Trend checklist (0–4)Top 26%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersBottom 36%
- Consecutive EPS beatsBottom 49%
- Share of analysts rating BuyBottom 10%
- Upside to consensus price targetBottom 26%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Top 18%
- Maximum drawdown, 3 yearsTop 45%
- Beta vs S&P 500 (lower is better)Top 21%
- Net debt / EBITDA (lower is better)Bottom 42%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | 4.6% | 5.7% | ↑ |
| Gross margin | 78.2% | 79.2% | ↑ |
| Operating margin | -14.8% | 2.5% | ↑ |
| FCF margin | 16.6% | 24.1% | ↑ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | 5.7% | 4.6% | ↑ | Bottom 42% |
| Gross margin | 79.2% | 78.2% | ↑ | Top 32% |
| Operating margin | 2.5% | -14.8% | ↑ | Top 38% |
| Net margin | 2.0% | -18.1% | ↑ | — |
| Free-cash-flow margin | 24.1% | 16.6% | ↑ | — |
| Return on invested capital | 1.4% | — | Top 30% | |
| Revenue growth, 3-year CAGR | 2.9% | — | Bottom 32% |
Quality of earnings and balance sheet
- Cash conversion (OCF / net income)Above 1× means profits are backed by cash.
- 3.00×
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- -13.9%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 7.5%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- +10.1 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- 1.80×
- Interest cover (operating income / interest)How many times operating profit covers interest.
- 1.3×
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- 14.56%
- Shareholder yield
- 14.56%
- Share count change, 1 year
- -11.3%
- Share count change, 3-year CAGR
- -8.2%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 4, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 1
- Beats in the last 8 reports
- 6 of 8
- Average EPS surprise, last 4
- -3.5%
- Average 2-day reaction, last 8
- -0.5%
- Positive 20 days after report
- 5 of 8
Analysts
- Consensus price target
- $29.40
- Target vs current price
- +17.4%
- Analysts with a rating
- 36
- Share rating Buy or Strong Buy
- 42%
- Consensus rating
- Hold
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 4, 2026 | +13.0% | +2.6% | -9.2% | -3.8% | — |
| Apr 30, 2026 | -1.6% | +1.4% | -5.8% | -5.8% | +5.3% |
| Feb 26, 2026 | -32.9% | -3.7% | -2.6% | +0.1% | +0.1% |
| Nov 6, 2025 | +7.7% | -3.4% | +9.2% | +9.7% | -3.8% |
| Aug 5, 2025 | +2.8% | -1.7% | +9.8% | +18.7% | -6.9% |
| May 8, 2025 | +8.8% | -1.1% | -2.9% | +6.2% | -8.9% |
| Feb 27, 2025 | +16.7% | -0.4% | -7.7% | -4.2% | +2.3% |
| Nov 6, 2024 | +9.7% | +2.3% | -2.8% | +10.5% | +53.9% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 4, 2026 | $0.73 | $0.65 | +13.0% | $192.4M |
| Apr 30, 2026 | $0.60 | $0.61 | -1.6% | $177.4M |
| Feb 26, 2026 | $0.57 | $0.85 | -32.9% | $196.9M |
| Nov 6, 2025 | $0.70 | $0.65 | +7.7% | $179.5M |
| Aug 5, 2025 | $0.74 | $0.72 | +2.8% | $181.1M |
| May 8, 2025 | $0.62 | $0.57 | +8.8% | $168.9M |
| Feb 27, 2025 | $0.91 | $0.78 | +16.7% | $187.3M |
| Nov 6, 2024 | $0.79 | $0.72 | +9.7% | $168.6M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| P/E (trailing) | 71.3× | 72.5× | 47th | Top 25% |
| P/E (forward) | 8.7× | — | — | — |
| EV / EBITDA | 10.4× | — | — | Top 10% |
| EV / Sales | 1.61× | — | — | Top 20% |
| Free-cash-flow yield | 18.10% | — | — | Top 3% |
| Earnings yield | 1.40% | — | — | Top 25% |
P/E over the past five years
Range 15.2× – 324.3× since Jun 30, 2021. Each point: price on the filing date divided by trailing-twelve-month EPS known then.
Technical state
Trend checklist
- ✓ Price above 20-day average
- ✗ Price above 50-day average
- ✓ Price above 200-day average
- ✓ 50-day average above 200-day
- ✓ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 34
- 50-day average slope (20 days)
- -0.7%
- 200-day average slope (20 days)
- +0.3%
- Distance from 50-day average
- -0.8%
- Distance from 200-day average
- +4.8%
- RSI (14)
- 49.2
- Relative volume
- 1.03×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 36.3%
- Volatility vs own 5-year history
- 48th percentile · Normal for this stock
- Beta vs S&P 500 (2 years, weekly)
- 0.59
- Correlation with S&P 500
- 0.24
- Current drawdown from 1-year high
- -9.3%
- Maximum drawdown, 3 years
- -67.0%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Apr 8, 2022 | Aug 9, 2024 | -85.7% | 586 days | Not yet recovered |
| Feb 24, 2021 | Oct 8, 2021 | -39.1% | 158 days | 124 days (Apr 6, 2022) |
| Sep 30, 2020 | Nov 6, 2020 | -16.1% | 27 days | 4 days (Nov 12, 2020) |
| Nov 20, 2020 | Dec 9, 2020 | -14.4% | 12 days | 19 days (Jan 7, 2021) |
| Jan 14, 2021 | Jan 29, 2021 | -14.4% | 10 days | 8 days (Feb 10, 2021) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $991.6M
- P/E (TTM)
- 71.3
- EPS, diluted (TTM)
- $0.35
- Revenue (TTM)
- $746.2M
- 52-week range
- $18.80 – $27.66
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $541.5M | $666.8M | $675.0M | $701.0M | $726.4M |
| Gross profit | $401.3M | $467.5M | $490.3M | $530.5M | $576.7M |
| Operating income | $89.9M | $60.0M | $87.7M | -$73.4M | $33.3M |
| Net income | $42.0M | $15.9M | $42.0M | -$99.6M | $7.0M |
| EPS (diluted) | $0.92 | $0.34 | $0.89 | -$2.15 | $0.16 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $168.6M | $187.3M | $168.9M | $181.1M | $179.5M | $196.9M | $177.4M | $192.4M |
| Net income | -$143.5M | $16.0M | $4.8M | -$4.8M | $5.4M | $1.6M | $2.9M | $4.7M |
| EPS (diluted) | -$3.11 | $0.34 | $0.10 | -$0.11 | $0.12 | $0.04 | $0.07 | $0.12 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | $125.7M | $145.3M | $154.6M | $189.4M | $152.0M |
| Capital expenditure | -$45.9M | -$30.1M | -$15.2M | -$10.6M | -$15.3M |
| Free cash flow | $79.9M | $115.2M | $139.5M | $178.8M | $136.7M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $26.7M | $27.3M | -$106,000 | -$25.0M | -$145.0M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $251.0M
- Total assets
- $1.24B
- Total liabilities
- $572.0M
- Total debt
- $412.1M
- Net debt
- $206.2M
- Shareholders’ equity
- $672.0M
As of Jun 30, 2026 (filed Aug 4, 2026).
Short interest
- Shares sold short
- 7,561,153
- Days to cover
- 12.98
- Change vs previous report
- +3.2%
FINRA short interest, settlement date Sep 15, 2026.